Annotation Detail

Information

Associated Genes: TP53
Associated Variants: TP53 WILD TYPE
TP53 WILD TYPE
Associated Disease: colorectal cancer
Source Database: CIViC Evidence
Description: In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab.
Variant Origin: N/A
Variant Origin: N/A
Evidence URL: https://civic.genome.wustl.edu/links/evidence_items/875
Gene URL: https://civic.genome.wustl.edu/links/genes/45
Variant URL: https://civic.genome.wustl.edu/links/variants/369
Rating: 3
Evidence Type: Predictive
Disease: Colorectal Cancer
Evidence Direction: Supports
Drug: Oxaliplatin,Capecitabine,Cetuximab
Evidence Level: B
Clinical Significance: Sensitivity/Response
Pubmed: 24957073

Drugs